Cancer Risks & Effects — BRCA Resource Guide

How to Read These Charts

The bar charts below compare cancer risk for BRCA mutation carriers against the general population. Longer bars mean higher risk. Ranges reflect variation across major studies.

BRCA1 Mutation

BRCA2 Mutation

General Population

Breast Cancer Risk in Women

Lifetime risk comparison

BRCA1

55–72%

BRCA2

45–69%

General Pop.

12.5%

Triple-negative breast cancer: 66–100% of breast cancers from BRCA1 mutations are triple-negative, an aggressive subtype that is harder to treat.

Ovarian Cancer Risk in Women

Risk by age 80 (includes fallopian tube and primary peritoneal cancer)

BRCA1

39–58%

BRCA2

13–29%

General Pop.

1.1%

Pancreatic Cancer Risk

Lifetime risk (affects both men and women)

BRCA1

~5%

BRCA2

5–10%

General Pop.

1.7%

Risks in Men

Half of all BRCA mutation carriers are male, yet men are tested at a fraction of the rate. The cancer risks are real.

BRCA1

BRCA2

General Population

Prostate Cancer (risk by age 80)

BRCA1

7–26%

BRCA2

19–61%

General Pop.

~16%

Male Breast Cancer (lifetime risk)

BRCA1

1–5%

BRCA2

5–10%

General Pop.

0.1%

Earlier and more aggressive: BRCA2-associated prostate cancers tend to appear a decade earlier and be more aggressive. Screening is recommended at age 40 for BRCA2 carriers, versus 50 for the general population.

Other Associated Cancers

🫜

Stomach Cancer

BRCA1: ~2.2x risk. BRCA2: ~3.7x risk. May be higher in women.

🔬

Colorectal

Suggestive link for BRCA1 carriers. Still under study with smaller samples.

⚠️

Second Cancers

Carriers who develop one cancer face elevated risk of a second, independent primary cancer.

☀️

Melanoma

Slightly elevated, particularly for BRCA2 carriers. Dermatological screening may help.

Key Context

<10%

of breast cancers involve a BRCA mutation

50%

of carriers are male, yet most are unaware

15%

of ovarian cancers are linked to BRCA

1%

of men with cancer get genetic testing vs. 52% of women

After a Positive Test

A positive result is not a diagnosis. It opens options for proactive risk management:

🔍

Enhanced Screening

Earlier, more frequent mammograms and MRIs, often from age 25

💊

Medications

Tamoxifen, raloxifene, or aromatase inhibitors to lower risk

🏥

Preventive Surgery

Mastectomy (90%+ risk reduction) or salpingo-oophorectomy

💬

PARP Inhibitors

Targeted drugs (Lynparza, Rubraca, Zejula) for BRCA cancers

👪

Family Testing

Cascade testing for relatives is simpler once a mutation is known

👥

Men's Screening

Prostate screening at 40, breast self-exam, pancreatic monitoring